Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
about
Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized MedicineComparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis.How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?Safety of inhaled long-acting anti-muscarinic agents in COPD.Dual bronchodilation and exacerbations of COPD.The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD.Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.The Challenges of Precision Medicine in COPD.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.Involvement of Allosteric Effect and K Channels in Crosstalk between β₂-Adrenergic and Muscarinic M₂ Receptors in Airway Smooth MuscleEffects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
P2860
Q33715841-F5D901E3-0E24-4460-BBB0-F1DFA7DBD788Q38608618-BD5A3415-0458-4699-BE18-ECED26385585Q38654745-292EBE2E-51A3-4590-8DD7-473FE068C030Q39030602-125890DD-CA52-4ABF-B8EB-F58632DB86ABQ39232425-823DBEE9-6320-46D9-B2B4-13974152023BQ42384700-6D06ADC4-497F-4647-AA43-E318B6E6DAEDQ47177016-36786C5F-91B4-4163-9D30-2ACA7AA2A3A6Q47664891-13AC0D8C-727D-4E17-8CE5-6539DD21267EQ47669469-3D98A9E9-B8AF-48BC-B88F-02077DCAC24FQ47962475-D38C4DFD-0404-4A46-909E-0FA8818ADEFAQ47966525-7F3A6542-310F-45DA-94B5-D71590640982Q48343204-5CFEDB58-DA82-48FE-9DAC-506FB33B974BQ55041230-3EAC8F92-320F-4209-90DA-36780CF4B9DDQ57095751-221BA2D3-1DAA-4D5E-BE66-6DE40846BD69Q57817674-C46131C7-3590-455E-AA42-01C84B09B7BD
P2860
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacological characterisati ...... nd bronchial epithelial cells.
@en
Pharmacological characterisati ...... nd bronchial epithelial cells.
@nl
type
label
Pharmacological characterisati ...... nd bronchial epithelial cells.
@en
Pharmacological characterisati ...... nd bronchial epithelial cells.
@nl
prefLabel
Pharmacological characterisati ...... nd bronchial epithelial cells.
@en
Pharmacological characterisati ...... nd bronchial epithelial cells.
@nl
P2093
P2860
P50
P1433
P1476
Pharmacological characterisati ...... nd bronchial epithelial cells.
@en
P2093
Francesco Facciolo
Josuel Ora
Maria Gabriella Matera
Mario Cazzola
P2860
P2888
P356
10.1186/S12931-016-0386-8
P577
2016-06-13T00:00:00Z
P6179
1002630196